Maxim Group Boosts SELLAS Life Sciences Group (NASDAQ:SLS) Price Target to $7.00

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) had its price objective upped by analysts at Maxim Group from $4.00 to $7.00 in a research note issued on Wednesday,Benzinga reports. The firm presently has a "buy" rating on the stock. Maxim Group's price target points to a potential upside of 295.48% from the company's previous close.

SELLAS Life Sciences Group Trading Down 6.8%

SELLAS Life Sciences Group stock traded down $0.13 on Wednesday, reaching $1.77. 2,857,645 shares of the stock were exchanged, compared to its average volume of 1,833,821. The firm has a fifty day moving average price of $1.78 and a two-hundred day moving average price of $1.42. The stock has a market cap of $176.61 million, a PE ratio of -4.66 and a beta of 2.31. SELLAS Life Sciences Group has a twelve month low of $0.77 and a twelve month high of $2.27.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.11) by $0.04. Equities analysts anticipate that SELLAS Life Sciences Group will post -0.57 EPS for the current fiscal year.

Insider Activity at SELLAS Life Sciences Group

In related news, Director Jane Wasman bought 20,000 shares of SELLAS Life Sciences Group stock in a transaction dated Friday, May 30th. The shares were bought at an average cost of $1.69 per share, for a total transaction of $33,800.00. Following the completion of the transaction, the director owned 30,400 shares of the company's stock, valued at approximately $51,376. This trade represents a 192.31% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 1.40% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Virtu Financial LLC increased its stake in SELLAS Life Sciences Group by 30.9% in the first quarter. Virtu Financial LLC now owns 53,861 shares of the company's stock valued at $58,000 after purchasing an additional 12,706 shares in the last quarter. Northern Trust Corp boosted its position in shares of SELLAS Life Sciences Group by 33.6% during the fourth quarter. Northern Trust Corp now owns 134,721 shares of the company's stock worth $140,000 after buying an additional 33,878 shares during the period. Brooklyn FI LLC bought a new position in shares of SELLAS Life Sciences Group during the fourth quarter worth about $677,000. Geode Capital Management LLC raised its position in SELLAS Life Sciences Group by 21.2% in the 4th quarter. Geode Capital Management LLC now owns 733,546 shares of the company's stock valued at $763,000 after buying an additional 128,355 shares during the last quarter. Finally, Anson Funds Management LP lifted its stake in SELLAS Life Sciences Group by 50.2% in the 4th quarter. Anson Funds Management LP now owns 1,192,266 shares of the company's stock valued at $1,240,000 after acquiring an additional 398,431 shares in the last quarter. Institutional investors own 17.38% of the company's stock.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.